1 terminated. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
Follow Relapsed Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-Cell Lymphoma trials Research Report on Relapsed Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 400mg ABT-199, Ibrutinib, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Hackensack Meridian Health | 10 | 2017-09-05 | 2024-09-23 |
Lymphoma, Large B-Cell, Diffuse (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Rituximab (1) · ibrutinib (1) · venetoclax (1)
Hackensack Meridian Health (1)
United States (1)
Andre Goy, MD (1)